This would be a good one for someone better than me to analyze. I'd guess short,but hell if I know.
Another perfect bubble pattern presents itself. By comparison APHA overlayed in yellow shows how similar and easy to recognize the pattern is. The only difference between the two is APHA happened about 2 years earlier (2017 vs. 2019) Whether the fundamentals stack up or not, the pattern is remarkably similar to other recent bubbles (last 2 years).
AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the...
EN: This sotck also woke up Friday, he could go reach my target. His lower trend line is very reliable. FR: Ce sotck aussi s'est réveillé vendredi, il pourrait aller atteindre ma cible. Sa ligne de tendance inférieure est très fiable.
EN : Last Friday, certainly announces a reversal and possibly a return to the top to reach the $ 35. At least four times, the stock has stumbled on its bottom line of mid-term trend andd Friday, it was probably the 5th time. FR: La journée de vendredi dernier annonce assurément un renversement et possiblement un retour vers le haut pour atteindre le 35$. Au moins...
I think this a possible count which offers a reasonable R:R
I think its reasonable to assume an ABC correction here given that wave 2 was a relatively short and small correction. Such correction would put us through the path of completing the fifth wave
Seems that 13.91 is acting as a tough support level. If that is broken, we have a pretty big fade coming.
I first started tracking AXSM on Monday Jan 7th (Pre-market at approx. $5.00), and it has since Sky-Rocketed to a high of $17.05 today pre-market Tuesday March 26th representing 248% in Gains, locking in enormous profits.
significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD) finance.yahoo.com